Now that Carl Icahn was able to score his big coup in shares of Imclone Systems, it is of little surprise that he is out rattling the cages at other biotech holdings. He has long been a holder and investor in this sector, but he has just over the last week or so increased his holdings in some biotech stocks.
One hike was in Enzon POharmaceuticals (NASDAQ: ENZN), where he took his stake to 7.3% from 6.93%. The company has nominated an Icahn affiliate for election to the board of directors.
Amylin Pharmaceuticals (NASDAQ: AMLN) also is reviewing a 13D filing as Carl Icahn is appointing 5 members to its board of directors. His stake went from 7.3% to 8.3%.
Cadus Corp. (NASDAQ-OTCBB: KDUS is one small stock where Icahn is involved and he just marginally increased his stake (very marginally) to 4.966+ million shares.
We have a full list of his biotech holdings from last year. We suspect Mr. Icahn has been active in others or is about to be.
Jon C. Ogg
January 29, 2009